Skip to main content
. 2017 Sep 7;88(5):254–263. doi: 10.5414/CN109031

Table 1. Patient characteristics overall and by hemoglobin variability group, 2004 and 2012 cohorts.
.

Hemoglobin variability groups*
Overall LL II HH LI IH LH
2004 2012 2004 2012 2004 2012 2004 2012 2004 2012 2004 2012 2004 2012
Total n 159,720 200,728 2165 2200 9646 18,999 3750 10,552 29,222 48,029 50,680 60,525 64,257 60,423
Age, mean, yrs. (SD) 62.3 (15.2) 63.0 (14.7) 55.9 (15.9) 58.2 (15.7) 63.7 (14.8) 65.2 (14.2) 62.1 (15.4) 57.8 (13.7) 61.5 (15.2) 63.3 (14.8) 62.9 (14.9) 63.4 (14.6) 62.1 (15.3) 62.9 (15.0)
Age
   0 – 44 13.9 11.6 25.3 19.9 11.6 8.6 15.0 16.6 15.1 11.5 12.7 10.8 14.4 12.2
   45 – 64 36 39.5 41.6 42.3 34.7 37.0 35.4 52.1 37.3 38.6 35.8 39.8 35.6 38.4
   65 – 74 26.3 25.0 19.6 22.0 27.2 26.2 26.3 19.2 25.7 25.5 26.7 25.0 26.3 25.2
   ≥ 75 23.8 23.9 13.5 15.8 26.6 28.1 23.4 12.1 22.0 24.5 24.9 24.3 23.6 24.2
Sex
   Female 48.7 46.0 46.1 44.9 45.9 47.5 43.7 22.7 49.0 49.7 47.3 43.2 50.55 49.6
   Male 51.3 54.0 54.0 55.1 54.1 52.5 56.3 77.3 51.0 50.3 52.7 56.8 49.44 50.4
Race
   White 53.4 53.1 48.5 45.8 58.5 54.9 51.3 53.8 54.7 51.6 53.4 55.0 52.36 52.0
   Black 40.3 40.3 46.6 48.8 35.0 37.6 41.6 40.3 39.2 41.3 40.3 38.9 41.32 41.4
   Other 6.3 6.6 4.9 5.4 6.5 7.5 7.1 5.9 6.2 7.0 6.3 6.1 6.32 6.6
Dialysis duration, mean, yrs. (SD) 4.1 (4.3) 5.6 (5.0) 4.9 (4.9) 5.9 (5.5) 4.2 (4.1) 5.4 (4.7) 3.9 (4.4) 7.1 (5.8) 4.4 (4.3) 5.6 (4.9) 4.0 (4.3) 5.5 (5.1) 4.0 (4.3) 5.4 (5.1)
Primary cause of ESRD
   Diabetes 42.8 44.6 35.1 35.9 43.4 46.5 42.4 36.2 42.7 45.3 42.9 44.7 43.0 45.2
   Hypertension 29.8 29.9 27.3 27.0 28.4 30.1 30.4 30.3 28.5 29.3 30.5 30.4 30.0 29.8
   Other 27.4 25.5 37.6 37.0 28.2 23.4 27.3 33.4 28.8 25.4 26.7 24.9 27.0 25.0
Hospitalization
   No 55.0 63.0 32.2 37.8 74.4 77.1 71.3 81.1 48.6 55.4 66.7 71.9 45.58 53.5
   Yes 45.0 37.0 67.8 62.2 25.6 22.9 28.7 18.9 51.5 44.6 33.3 28.1 54.42 46.5
Total hospital days, mean, yrs. (SD) 5.0 (9.6) 4.1 (8.6) 12.3 (16.8) 10.9 (15.3) 1.9 (5.4) 1.9 (5.2) 2.1 (5.6) 1.4 (4.3) 6.7 (11.5) 5.6 (10.4) 2.7 (6.3) 2.5 (6.0) 6.4 (10.4) 5.6 (9.8)
Comorbidity
   ASHD 31.4 32.8 34.9 39.9 24.0 26.5 25.4 21.6 34.0 36.2 26.8 29.2 35.2 37.4
   CHF 29.0 29.4 42.9 46.0 19.3 22.4 20.4 16.5 33.4 34.4 22.9 24.3 33.3 34.5
   CVA/TIA 10.3 11.6 12.1 12.3 6.6 8.4 6.9 5.2 11.1 13.0 8.2 9.6 12.3 14.4
   PVD 24.0 26.6 31.3 34.5 16.1 20.0 18.7 19.0 26.9 29.3 19.6 23.1 27.5 31.1
   Other cardiac 21.5 19.6 35.8 35.8 14.6 13.9 14.0 10.6 25.7 23.9 16.1 15.0 24.8 23.6
   COPD 12.8 16.0 18.0 25.3 8.0 11.4 9.3 9.6 15.0 18.5 9.8 13.4 14.9 18.8
   GI bleeding 6.5 6.0 16.3 18.5 2.8 2.8 2.8 2.1 8.2 8.0 3.6 3.5 8.3 8.0
   Liver disease 7.8 6.0 13.8 11.9 7.5 4.9 6.7 5.3 8.7 6.1 6.7 5.8 8.1 6.3
   Dysrhythmia 19.6 23.9 27.4 34.0 15.2 19.4 15.3 17.2 22.3 27.1 16.2 21.0 21.8 26.5
   Cancer 5.4 6.0 9.3 13.2 4.8 5.1 3.6 3.1 6.1 7.5 4.3 4.8 5.9 6.6
   Diabetes 55.0 61.1 51.1 57.0 53.0 61.5 51.7 49.4 55.5 62.9 53.6 59.9 56.3 62.8

Unless otherwise indicated, data are percentages. LL = consistently low; LI = low-intermediate; LH = low-high; HH = consistently high; IH = intermediate-high; II = consistently intermediate; ASHD = atherosclerotic heart disease; CHF = congestive heart failure; COPD = chronic obstructive heart disease; CVA/TIA = cerebrovascular accident/transient ischemic attack; ESRD = end-stage renal disease; GI = gastrointestinal; PVD = peripheral vascular disease.